Cardio Diagnostics (NASDAQ:CDIO) Issues Quarterly Earnings Results

Cardio Diagnostics (NASDAQ:CDIO) issued its quarterly earnings data on Friday. The company reported ($0.63) earnings per share for the quarter, Zacks reports. Cardio Diagnostics had a negative return on equity of 71.75% and a negative net margin of 40,612.50%.

Cardio Diagnostics Trading Down 7.7%

Shares of NASDAQ CDIO traded down $0.13 during trading hours on Friday, reaching $1.55. The stock had a trading volume of 65,091 shares, compared to its average volume of 62,483. The firm has a market cap of $4.59 million, a price-to-earnings ratio of -0.42 and a beta of 2.30. The business’s fifty day moving average price is $2.33 and its two-hundred day moving average price is $2.69. Cardio Diagnostics has a 52-week low of $0.97 and a 52-week high of $7.91.

Institutional Trading of Cardio Diagnostics

An institutional investor recently bought a new position in Cardio Diagnostics stock. Citadel Advisors LLC purchased a new stake in Cardio Diagnostics Holdings, Inc. (NASDAQ:CDIO) in the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund purchased 19,520 shares of the company’s stock, valued at approximately $79,000. Citadel Advisors LLC owned 1.07% of Cardio Diagnostics as of its most recent filing with the Securities and Exchange Commission (SEC). 8.06% of the stock is currently owned by institutional investors and hedge funds.

Analyst Ratings Changes

Separately, Wall Street Zen raised Cardio Diagnostics to a “hold” rating in a research note on Saturday, March 21st. One analyst has rated the stock with a Sell rating, According to MarketBeat, the company has a consensus rating of “Sell”.

Cardio Diagnostics Company Profile

Cardio Diagnostics Holdings, Inc develops and commercializes epigenetics-based clinical tests for cardiovascular disease. It offers Epi+Gen CHD, a three-year symptomatic coronary heart disease (CHD) risk assessment test targeting CHD events, including heart attacks; and PrecisionCHD, an integrated epigenetic-genetic blood test for the early detection of coronary heart disease. Cardio Diagnostics Holdings, Inc was founded in 2017 and is headquartered in Chicago, Illinois.